Sandoz Partners with Elawan Energy on 150 MW Spanish Solar Project to Power Nearly 90% of European Operations

Sandoz Partners with Elawan Energy on 150 MW Spanish Solar Project to Power Nearly 90% of European Operations

(IN BRIEF) Sandoz has signed a 10-year virtual PPA with Elawan Energy to develop 150 MW of new solar capacity in Valladolid, Spain, expected to meet almost 90% of electricity demand for its European operations. This partnership is a key milestone in the company’s global decarbonization strategy, which also includes other renewable energy agreements across its manufacturing network. The initiative supports Sandoz’s formal commitment to the Science Based Targets initiative, with a carbon reduction plan due for validation in early 2026, and highlights its dedication to sustainable, climate-conscious operations.

(PRESS RELEASE) BASEL, 12-Aug-2025 — /EuropaWire/ — Sandoz (SIX:SDZ/OTCQX:SDZNY), a global leader in generic and biosimilar medicines, has taken a major step in its decarbonization journey with the signing of a 10-year virtual Power Purchase Agreement (PPA) with renewable energy company Elawan Energy. The agreement will see the development of new solar facilities in Valladolid, Castilla y León, Spain, with a total installed capacity of 150 MW, capable of covering almost 90% of the electricity needs for Sandoz’s European operations.

Europe hosts the majority of Sandoz’s manufacturing and operational sites, making the agreement a pivotal move toward meeting the company’s sustainability goals. Under the arrangement, Sandoz and Elawan Energy will work together to bring the solar projects online, generating clean energy that will significantly cut the company’s carbon footprint.

“Environmental sustainability is embedded in the way we work,” said Glenn Gerecke, Chief Manufacturing and Supply Officer at Sandoz. “This collaboration with Elawan Energy is a tangible example of how we are putting that commitment into action. By meeting nearly 90% of our European electricity demand with solar energy, we will substantially reduce our environmental impact while advancing toward a more sustainable future.”

The initiative complements other renewable energy measures across Sandoz’s global operations, including similar PPAs supporting multiple production sites. It also aligns with the company’s broader climate objectives, which include a formal pledge to the Science Based Targets initiative (SBTi) to set verified carbon reduction goals. This commitment, announced in 2024, will be supported by a detailed emissions reduction plan submitted to the SBTi for validation by January 2026.

Through this latest agreement, Sandoz reinforces its position as a pharmaceutical industry leader in climate responsibility, demonstrating how large-scale renewable energy adoption can integrate seamlessly into global manufacturing and supply operations.

DISCLAIMER
This Media Release contains forward-looking statements, which offer no guarantee with regard to future performance. These statements are made on the basis of management’s views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside of the control of Sandoz. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Each forward-looking statement speaks only as of the date of the particular statement, and Sandoz undertakes no obligation to publicly revise any forward-looking statements, except as required by law.

ABOUT SANDOZ
Sandoz (SIX: SDZ; OTCQX: SDZNY) is the global leader in generic and biosimilar medicines, with a growth strategy driven by its Purpose: pioneering access for patients. More than 20,000 people of 100 nationalities work together to ensure 900 million patient treatments are provided by Sandoz, generating substantial global healthcare savings and an even larger social impact. Its leading portfolio of approximately 1,300 products addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886. Its history of breakthroughs includes Calcium Sandoz in 1929, the world’s first oral penicillin in 1951, and the world’s first biosimilar in 2006. In 2024, Sandoz recorded net sales of USD 10.4 billion.

MEDIA CONTACTS:

SOURCE: Sandoz